ImmunityBio, Inc. (IBRX) shares tumbled 8.3% to $8.42 as of October 19, 2026, a significant decline from the prior close of $9.18. BestStocks flagged the session as a major change for IBRX. The move is tied to price move down. Below, we break down what changed for IBRX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
IBRX fell 8.3% to $8.42
IBRX moved -8.38% from its $9.19 open to a $8.42 close on 2026-10-19. Monitor next session.
This summary describes the catalyst and move as first detected on Oct 19, 2026, 4:50 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsMedium confidence
Rel. volume
1.7×
Above Avg
Vs peers
—
No comparable peers
Market cap
$8.9B
NASDAQ Global Select
Analyst target
$14
+66.3% vs price
Price chart
Sep 18 – Oct 19
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for ImmunityBio, Inc. investors
For ImmunityBio, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Material negative event; Sharp 8.3% decline — elevated risk. Wall Street's consensus price target sits at $14.00, implying +66.3% upside from $8.42. BestStocks rates the overall signal quality medium (64/100). With earnings roughly 15 days out, the next report is the most likely near-term test of the move.
IBRX price reaction
IBRX last traded at $8.42, down $0.76 (-8.28%) from the previous close of $9.18. The session traded on 1.7× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $8.42 and $10.51, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on ImmunityBio, Inc. (IBRX)
▼Latest catalyst·a bearish counterpoint
The latest catalyst — a materially negative development — a bearish counterpoint that challenges the prevailing bullish analyst view.
The consensus analyst price target on ImmunityBio, Inc. (IBRX) is $14.00, 66.3% above the recent $8.42. Over the past 90 days analysts logged 0 upgrades, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on IBRX line up.
▲ The bullish case
+Wall Street's consensus price target of $14.00 implies +66.3% upside from $8.42.
+The Street's most bullish target is $16.00 (+90.0%).
+Positive price momentum.
+ImmunityBio shares surged 9.74% to $9.69 on September 30, 2026, driven by a technical breakout above resistance and growing optimism around its cancer immunotherapy pipeline, according to the ImmunityBio News Hub cited by Yahoo Finance.
▼ The bearish case
−Material negative event.
−Sharp 8.3% decline — elevated risk.
−ImmunityBio, Inc. (IBRX) moved -6.94% from $8.07 to $7.51 on 2026-07-22.
−ImmunityBio (IBRX) fell 9.60% to $8.53 intraday, according to FMP delayed data.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Material / Earnings2026-10-16-8.2%
ImmunityBio, Inc. (IBRX) moved -8.20% from $10.00 to $9.18 on 2026-10-16, the same day the FDA expanded ANKTIVA's approved indication to include BCG-unresponsive non-muscle-invasive bladder cancer patients with papillary-only tumors, broadening the eligible patient population.
News2026-10-14+1.1%
FDA expanded ANKTIVA approval for BCG-unresponsive bladder cancer to include both papillary and CIS disease.
ImmunityBio announced participation in the Piper Sandler Virtual Oncology Symposium, with Founder and Executive Chairman Dr. Patrick Soon-Shiong scheduled to present (Business Wire, 2026-10-08). The stock rose 5.40% to $10.45 on volume of 7.9M shares (1.63x historical average for this time of day), suggesting investor interest in the company's clinical or commercial updates ahead of the event.
Material / Earnings2026-10-06-6.6%
ImmunityBio, Inc. (IBRX) moved -5.46% from $10.25 to $9.69 on 2026-10-06. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was identified. Volume traded near its 5-day average, suggesting routine selling rather than a shock event.
ImmunityBio rose 8.89% to $10.11, driven by retail investor momentum and anticipation of an FDA label-expansion decision for its cancer immunotherapy ANKTIVA scheduled for January 6, 2027, according to the web catalyst. Volume surged to 22.6 million shares (2.69x the time-adjusted average), reflecting elevated speculative interest.
ImmunityBio shares surged 9.74% to $9.69 on September 30, 2026, driven by a technical breakout above resistance and growing optimism around its cancer immunotherapy pipeline, according to the ImmunityBio News Hub cited by Yahoo Finance. Volume spiked to 20.3M shares — 2.50x the time-adjusted daily average — reflecting elevated institutional and retail interest tied to the company's $5.8B addressable market opportunity and chairman Patrick Soon-Shiong's broader cancer-immunotherapy initiatives.
Material / Earnings2026-09-23-7.1%
IBRX moved -6.70% from its $9.25 open to a $8.63 close on 2026-09-23.
In-depth IBRX event analyses
Permanent, dated analyses of IBRX's most significant sessions.
IBRX tumbled 8.3% to $8.42. The move is associated with price move down.
How much did IBRX stock fall?
IBRX lost 8.28% ($0.76) versus the prior close of $9.18, last trading at $8.42 on 1.7× average volume.
When is ImmunityBio, Inc.'s next earnings date?
IBRX's next earnings report is estimated for 2026-11-03 — about 15 days away.
What is the analyst price target for IBRX?
The consensus analyst price target for IBRX is $14.00, about 66.3% above the current $8.42. Over the past 90 days, analysts recorded 0 upgrades, 2 maintains, and 0 downgrades.
How BestStocks tracks IBRX
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for IBRX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
